CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Makers Laboratories Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Makers Laboratories Ltd
54 D, Kandivli Indl Estate
Charkop,Kandivli West
Phone: +91 2228688544p:+91 2228688544 MUMBAI, 400067  India Ticker: 506919506919
Business Summary
Makers Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceuticals. The Company operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensives, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2869 Industrial organic chemicals, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board R. K.Verma 2/13/2019 2/13/2019
Chief Executive Officer, Whole-Time Director SaahilParikh 46 10/30/2017 8/11/2011
Manager - Accounts, Chief Financial Officer SandeepKadam 54 10/30/2017 10/30/2017
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 121 (As of 3/31/2023)
Outstanding Shares: 5,900,376 (As of 9/30/2023)
Shareholders: 4,591
Stock Exchange: BOM
Fax Number: +91 2228688544


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024